{"filing":{"accession_number":"0001372514-26-000063","cik":"0001372514","ticker":"KPHMW","company_name":"KIORA PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"kprx-20260618.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251426000063/kprx-20260618.htm"},"events":[{"id":11689,"run_id":10272,"accession_number":"0001372514-26-000063","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The disclosure announces preclinical data demonstrating that KIO-300 significantly suppressed seizure activity in an ex vivo temporal lobe epilepsy model, with statistically significant results (p \u003c 0.0001). While this represents early-stage research outside the company's primary ophthalmology focus, the data suggests potential therapeutic expansion into neurology and epilepsy treatment. This is material to investors as it expands the perceived value of the ion channel modulator platform beyond retinal disease, though it does not fit neatly into the standard event taxonomy (not an earnings release, M\u0026A activity, executive change, or other specifically defined categories).","company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPHMW","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8340,"accession_number":"0001372514-26-000063","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces preclinical data demonstrating that KIO-300 significantly suppressed seizure activity in an ex vivo temporal lobe epilepsy model, with statistically significant results (p \u003c 0.0001). While this represents early-stage research outside the company's primary ophthalmology focus, the data suggests potential therapeutic expansion into neurology and epilepsy treatment. This is material to investors as it expands the perceived value of the ion channel modulator platform beyond retinal disease, though it does not fit neatly into the standard event taxonomy (not an earnings release, M\u0026A activity, executive change, or other specifically defined categories).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T11:04:11.051807+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8340,"accession_number":"0001372514-26-000063","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces preclinical data demonstrating that KIO-300 significantly suppressed seizure activity in an ex vivo temporal lobe epilepsy model, with statistically significant results (p \u003c 0.0001). While this represents early-stage research outside the company's primary ophthalmology focus, the data suggests potential therapeutic expansion into neurology and epilepsy treatment. This is material to investors as it expands the perceived value of the ion channel modulator platform beyond retinal disease, though it does not fit neatly into the standard event taxonomy (not an earnings release, M\u0026A activity, executive change, or other specifically defined categories).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T11:04:11.051807+00:00","company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPHMW","filing_date":"2026-06-18"}]}